Core Viewpoint - Enwei Pharmaceutical (301331.SZ) announced its participation as a limited partner in establishing the Jiaxing Panlin Jiayi Venture Capital Partnership (Limited Partnership) with a capital commitment of 20 million yuan [1] Investment Details - The total scale of the fund is 201 million yuan, focusing on investments in healthcare (innovative drugs, innovative medical devices) and technology (enterprise-level services, hard technology) [1] - The partnership still needs to complete the registration with the Asset Management Association of China and the business change registration, indicating uncertainty in the implementation process [1] Investment Risks - The company’s investment may face a longer investment return period, as well as risks related to the inability of investment projects to achieve expected returns or potential investment failures [1]
恩威医药最新公告：拟出资2000万元与专业投资机构共同设立基金